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Abstract
Background: Duchenne muscular dystrophy (DMD) is a sex-linked inherited muscle disease characterized by a
progressive loss in muscle strength and respiratory muscle involvement. After 12 years of age, lung function
declines at a rate of 6 % to 10.7 % per year in patients with DMD. Steroid therapy has been proposed to delay the
loss of motor function and also the respiratory involvement.
Method: In 21 patients with DMD aged between seven and 16 years, the forced vital capacity (FVC) and the forced
expiratory volume in one second (FEV1) were evaluated at three different times during a period of two years.
Results: We observed in this period of evaluation the maintenance of the FVC and the FEV1 in this group of
patients independently of chronological age, age at onset of steroid therapy, and walking capacity.
Conclusion: The steroid therapy has the potential to stabilize or delay the loss of lung function in DMD patients
even if they are non-ambulant or older than 10 years, and in those in whom the medication was started after
7 years of age.
Keywords: Duchenne muscular dystrophy, Steroids, Vital forced capacity, Respiratory function tests, Myopathies
Background
Duchenne muscular dystrophy (DMD) is one of the
most common inherited pediatric neuromuscular dis-
orders, affecting 1 in 3,500 live male births. It is an
X-linked disorder caused by mutations in the dys-
trophin gene and is characterized by a progressive de-
crease in muscle strength and motor function [1,2].
Besides the impairment of motor function, one major
problem is the progressive involvement of the respira-
tory muscles which leads to secondary changes such
as atelectasis, decreased lung compliance, ineffective
cough and occurrence of repeated infections, as well as
imbalance in ventilation-perfusion and hypoxia during
sleep [3,4].
Patients with DMD develop a restrictive respiratory
pattern with reduction of maximal respiratory pressures
and forced vital capacity (FVC) that implicates a risk
for respiratory failure and death [2,5]. Consequently,
measures of lung function are fundamental methods to
monitor the outcome of patients [6]. Pulmonary func-
tion of patients with DMD increases until the age of
10 to 12 years and then reaches a plateau. This in-
crease reflects the growth of the entire rib cage, includ-
ing its muscles and ligaments [7,8]. Following the
plateau phase, lung function declines at a rate of 6-8 %
annually [6-10]. A recent study shows a decrease of
vital capacity of 10.7 % per year in patients with DMD
[11].
Steroid therapy has been used to slow the progression
of the disease with many studies showing a delay in
motor impairment from six months to three years [12-
16]. Although it is still uncertain how long steroids can
slow the progression of respiratory impairment, retro-
spective studies of long-term monitoring in patients with
DMD have documented the maintenance of lung func-
tion for a long period [14,15]. The aim of our study was
to evaluate longitudinally the pulmonary function in
DMD patients on steroid therapy and its relation to age,
motor ability (ambulant or not), and age at the onset of
steroid therapy.
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Methods
Study design
We evaluated 30 boys with DMD who were between
seven and 23 years of age. The diagnosis of DMD was
confirmed by molecular analysis and/or by imunohisto-
chemistry and Western blot of dystrophin in muscle bi-
opsy. All children were being treated with deflazacort
(0.9 mg/kg/day once daily) or prednisolone (0.75 mg/kg
per day intermittently 10 days on/10 days off ). A control
group was not included in this study because most of
our patients had submitted to steroid treatment. Patients
were excluded from the study in the following circum-
stances: tracheotomy, smokers, respiratory infection or
other pulmonary diseases, and discontinuation of the
steroid therapy during the study. The term of consent
was signed by the parents and approved by the Ethics
Committee for Analysis of Research Projects of our
Institution.
Patients were classified according to the age of evalu-
ation [10 years of age or younger (≤10 years), and older
than 10 years of age (>10 years)], age of onset of steroid
therapy [seven years of age or younger (≤7 years), and
older than seven years of age (>7 years)] and walking
capacity (ambulant and non-ambulant). The height of
ambulant patients was measured in a standing position,
with correction of the equines support when possible;
when not, height was estimated using the length of the
arm span. The tests were performed by the same physio-
therapist using a spirometer (microQuark, Cosmed,
Italy) coupled to a microcomputer with daily calibration.
Three evaluations were performed, all on the days of
regular medical appointments. The patients were
assessed initially at the first evaluation; and the second
and third evaluations, respectively, were performed one
and two years later.
Pulmonary function testing
Measurements were performed with the patient in the
sitting position, following the recommendations of the
American Thoracic Society and the European Respira-
tory Society (ATS/ERS) [17]. Up to eight tests were per-
formed, with an interval of rest of one minute or more
(if necessary). We selected the three best performances
with a maximum variability of 5 % or 200 ml between
them. The parameters evaluated were FVC and forced
expiratory volume in 1 sec (FEV1), both expressed as ab-
solute and relative values. The relative values were
obtained by comparison with normal values for all spiro-
metric variables [18]. Statistical analysis was performed
using the analysis of variance (ANOVA) with repeated
measures to compare the average results obtained in the
groups of patients (group effect) and among the three
different periods of evaluation (time effect). When the
covariance matrix of the observations of the same
individual was not found, the tests were adjusted based
on Huynh-Feldt correction. An index of significance of
5 % (p < 0.05) was adopted and it was verified if there
was interaction among the results.
Results
Of the 30 patients who were evaluated initially, only 21
were monitored for the entire period of two years.
Patients were excluded because they failed to use medica-
tion regularly or because they failed to attend the evalua-
tions. The age of the 21 patients that concluded the study
varied from 7 to 16 years. The mean age of the first
recording was 11.6 ± 3 years. The mean height and
weight, respectively, were 142.8 ± 15.0 cm and
35.6 ± 9.1 kg at the first evaluation and 147.8 ± 14.2 cm
and 40.7± 9.5 kg at the last visit. The mean body mass
index was 17.5 ± 3.4 at the first evaluation and 18.7 ± 3.6
at the last visit. The average age at the loss of walking
capacity was 10.7± 2.7 years. None patient had been sub-
mitted to spinal surgery, most of the patients (86 %)
attended physiotherapy sections and a small proportion
of them (24 %) also attended respiratory therapies. Seven
patients (33 %) performed an air stacking maneuver at
home and during physical therapy sessions and two
(10 %) utilized non-invasive ventilation (NIV) at night.
The average age of onset of steroid therapy was
8.05± 3.06. Ten patients (48 %) started the medication
with ≤7 years and 11 (52 %) after this age. Only two
patients started the drug after the loss of walking capacity.
One was 16 years old and initially had absolute and rela-
tive values of FVC of 0.4 L and 36.9 %, respectively, and
at the last visit, 0.89 L and 34.7 %, respectively. The other
was 15 years old and initially showed absolute and relative
values of FVC of 1.33 L and 43.6 %, respectively, and
1,43 L and 54.9 %, respectively, at the end of follow up.
In relation to the three times of evaluation, the FVC
and FEV1 expressed in absolute and relative values
showed no statistically significant change either in
patients ≤10 years or those older than 11 years (Tables 1
and 2, Figure 1 and 2). Also, in patients who started the
steroid therapy with ≤7 years and after of this age, as
well as in ambulant and non-ambulant patients, no sig-
nificant changes were observed (Tables 1 and 2). Com-
paring the groups of patients according to age
(≤10 years and >10 years), age of onset of therapy
(≤7 years and >7 years), and walking capacity (ambulant
and non-ambulant), lung function did not show any sta-
tistically significant differences (p > 0.05). In addition,
interaction in the results of each group tested was not
observed (Tables 1 and 2).
Discussion
Our study demonstrated the maintenance of lung func-
tion for a period of up to two years in patients with
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DMD treated with steroids regardless of age, walking
capacity, and age of onset of therapy. We were not able
to confirm that steroid therapy alone is responsible for
the maintenance of lung function, due to the lack of a
control group. According to McDonald et al., [9] the loss
of walking ability and spinal deformities can affect lung
function but age is the most important factor. Regarding
age, we have detected that in patients older than 10 years,
lung function was maintained without significant
changes during a period of up to two years, while in
the natural history of disease, lung volumes typically
decline about 6 % to 10.7 % per year after 10 years of
Table 1 Forced Vital Capacity (FVC) in three times of evaluation according to the age (≤10 years and >10 years), age
of onset of steroid therapy (≤7 years and >7 years), and walking capacity (ambulant and non-ambulant)
FVC (L/%)
Evaluation
I
Evaluation
II
Evaluation
III
Age (≤10 years)
n= 9
1.6 ± 0.3/
78.8 ± 12.5
1.7 ± 0.4/
80.1 ± 16.6
1.7 ± 0.4/
75.2 ± 20.2
p1 = 0.24/0.59
p2 = 0.07/0.31
Age (>10 years)
n= 12
1.7 ± 0.4/
66 ± 22.1
1.8 ± 0.4/
65.5 ± 24.7
1.7 ± 0.4/
60.5 ± 23.6
p3 = 0.19/0.09
Age of onset of steroid 1.6 ± 0.3 /
75.9 ± 16.3
1.7 ± 0.5 /
78.5 ± 22.5
1.7 ± 0.4 /
74.7 ± 25.5
p1 = 0.24/0.61
therapy (≤7 years) p2 = 0.05/0.25
p3 = 0.21/0.23
n= 10
Age of onset of steroid 1.7 ± 0.4 /
66.9 ± 21.3
1.8 ± 0.4 /
66.1 ± 21.7
1.7 ± 0.3 /
59.6 ± 18.5therapy (>7 years)
n= 11
Ambulant 1.7 ± 0.4 /
86.2 ± 10.6
1.9 ± 0.4 /
92.3 ± 11.5
1.9 ± 0.3 /
87.2 ± 15.6
p1 = 0.37/0.65
p2 = 0.41/0.99
p3 = 0.83/0.67n= 9
Non-ambulant 1.6 ± 0.4 /
60 ± 16.3
1.6 ± 0.4 /
56.7 ± 15.1
1.5 ± 0.3 /
51.5 ± 13.3n= 12
Table legend: p1 = comparison between the three evaluations, p2 = comparison between both groups, p3 = interaction effect.
Table 2 Forced Expiratory Volume in 1 sec (FEV1) in three times of evaluation according to the age (≤10 years and
>10 years), age of onset of steroid therapy (≤7 years and >7 years), and walking capacity (ambulant and non-ambulant)
FEV1 (L/%)
Evaluation
I
Evaluation
II
Evaluation
III
Age (≤10 years) 1.3 ± 0.3/
72.5 ± 17.14
1.5 ± 0.5/
77.4 ± 20.8
1.3 ± 0.4/
69.1 ± 22
p1 = 0.35/0.43
n= 9 p2 = 0.16/0.17
p3 = 0.13/0.16Age (>10 years) 1.5 ± 0.4/
64.3 ± 20.6
1.5 ± 0.3/
64.5 ± 22.5
1.5 ± 0.3/
61.8 ± 22.3
n= 12
Age of onset of steroid 1.3 ± 0.3 /
71.6 ± 19.1
1.5 ± 0.5 /
76.2 ± 24.8
1.4 ± 0.5 /
72.1 ± 26.6
p1 = 0.32/0.38
therapy (≤7 years) p2 = 0.05/0.22
p3 = 0.18/0.18n= 10
Age of onset of steroid 1.5 ± 0.4 /
64.3 ± 19.6
1.5 ± 0.3 /
64.3 ± 19
1.4 ± 0.2 /
58.5 ± 15.2therapy (>7 years)
n= 11
Ambulant 1.4 ± 0.3 /
80.4 ± 13.9
1.6 ± 0.4 /
87.8 ± 15.9
1.6 ± 0.3 /
82.1 ± 19.1
p1 = 0.42/0.41
p2 = 0.18/0.98
p3 = 0.50/0.38n= 9
Non-ambulant 1.4 ± 0.4 /
58.3 ± 17.5
1.4 ± 0.4 /
56.7 ± 16.1
1.3 ± 0.3 /
52.2 ± 13.9n= 12
Table legend: p1 = comparison between the three evaluations, p2 = comparison between both groups, p3 = interaction effect.
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age [6,9-11]. This finding clearly demonstrated the effi-
cacy of the steroid therapy in delaying respiratory deteri-
oration in these patients, even when they are older than
10 years of age.
Steroids conventionally are used in order to increase
the walking period. However, some authors have sug-
gested that the treatment should be continued in wheel-
chair patients due to the potential effect of the
medication in preventing spinal deformity and the de-
terioration of respiratory function [15,19-21]. In our
study, both wheelchair-bound patients and ambulant
patients showed stability of the respiratory parameters,
which demonstrates the maintenance of lung function in
steroid-treated patients, even after the loss of walking
capacity.
The optimal age to begin steroid treatment in order to
preserve respiratory function is poorly defined. In the-
ory, the use of the steroids at the initial stages of the dis-
ease could prevent the development of disabilities,
including the deterioration of lung function. We evalu-
ated respiratory function in patients who started steroid
therapy ≤7 years and >7 years of age in order to verify
the possible influence of the age of onset of therapy on
the evolution of lung function. Both groups showed
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Figure 1 Individual values of Forced Vital Capacity (FVC) were expressed in % of the predicted value. After the Evaluation I (baseline),
patients were followed yearly (evaluations II and III). Patients were divided in 2 groups according their age (7–10 years and 11–16 years).
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Figure 2 Individual values of Forced Expiratory Volume in 1 sec (FEV1) were expressed in % of the predicted value. After the Evaluation I
(baseline), patients were followed yearly (evaluations II and III). Patients were divided in 2 groups according their age (7–10 years and 11–16 years).
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stability of FVC and FEV1, which indicates that steroid
treatment might stabilize lung function even in those
children who are first treated when they are older than
7 years of age. Longer follow-up is necessary to clarify
the best time to start the medication.
Although not as sensitive as the maximum inspiratory
pressure (MIP) and maximum expiratory pressure
(MEP), FVC and FEV1 give good information on the re-
duction of pulmonary compliance and chest wall dy-
namic, which reflects the state of the bronchi and
requiring muscle power to obtain maximum values.
Therefore, FVC and FEV1 provide useful and reprodu-
cible measures of the progression of the disease [3,6].
Furthermore, FEV1 and MIP are strongly correlated
[10,11]. Possibly, a longer follow-up would determine
how long pulmonary function and respiratory muscle
strength remain stable in DMD patients treated with
steroids. Some of our patients performed the “air stack-
ing” maneuver at home or during physiotherapy. How-
ever, we did not determine how frequently the maneuver
was performed or the influence of the maneuver on pul-
monary parameters. The “air stacking” maneuver is
reported to have positive effects only in peak flow of
cough and maximum insufflation capacity [22,23]. The
CVF continued to decline independently of the use of
this maneuver [23]. Only a small number of our patients
used non-invasive ventilation (NIV) during sleep. There-
fore, we could not analyze the effects of NIV.
This study present 2 limitations: first, the period of fol-
low up may be considered short (2 years); however, most
study evaluating the effect of corticosteroid in motor im-
pairment in DMD patients have studied such period of
time [20,21]. Second, the absence of control could repre-
sent a limitation; however, there are studies demonstrat-
ing that corticosteroid improves motor function in
DMD patients and for ethical reasons a control group
was considered inadequate by our hospital´s ethical
committee.
Conclusion
Our study has shown that steroid treatment has the po-
tential to stabilize lung function in DMD patients even
in non-ambulant children, in those older than 10 years
and in those in which the medication was started after
7 years of age.
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